Rapport Therapeutics (NASDAQ:RAPP) Earns “Buy” Rating from HC Wainwright

Rapport Therapeutics (NASDAQ:RAPP)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research report issued to clients and investors on Tuesday, MarketBeat reports. They currently have a $66.00 target price on the stock. HC Wainwright’s price objective points to a potential upside of 118.32% from the company’s current price.

RAPP has been the subject of a number of other research reports. Wall Street Zen lowered shares of Rapport Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. BTIG Research boosted their target price on shares of Rapport Therapeutics from $75.00 to $89.00 and gave the stock a “buy” rating in a research report on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Rapport Therapeutics in a research report on Thursday. Citigroup reissued a “market outperform” rating on shares of Rapport Therapeutics in a research report on Wednesday, September 23rd. Finally, Raymond James Financial reissued a “strong-buy” rating on shares of Rapport Therapeutics in a research report on Tuesday, September 22nd. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $65.00.

Rapport Therapeutics Trading Up 5.7%

Rapport Therapeutics stock traded up $1.63 on Tuesday, reaching $30.23. 6,368,276 shares of the stock were exchanged, compared to its average volume of 382,987. The stock has a market cap of $1.45 billion, a PE ratio of -10.00 and a beta of 1.22. Rapport Therapeutics has a twelve month low of $23.75 and a twelve month high of $52.93. The firm has a fifty day moving average price of $40.70 and a two-hundred day moving average price of $39.14.

Rapport Therapeutics (NASDAQ:RAPP) last released its earnings results on Wednesday, August 5th. The company reported ($1.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.07). Equities analysts anticipate that Rapport Therapeutics will post -4.09 EPS for the current fiscal year.

Insider Transactions at Rapport Therapeutics

In other news, CEO Abraham Ceesay sold 28,958 shares of the company’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $48.01, for a total transaction of $1,390,273.58. Following the completion of the transaction, the chief executive officer owned 486,108 shares of the company’s stock, valued at approximately $23,338,045.08. This represents a 5.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Cheryl Gault sold 10,000 shares of the company’s stock in a transaction dated Wednesday, September 30th. The shares were sold at an average price of $33.19, for a total transaction of $331,900.00. Following the transaction, the chief operating officer directly owned 139,914 shares of the company’s stock, valued at $4,643,745.66. This represents a 6.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 97,976 shares of company stock valued at $4,420,349 in the last ninety days. 12.48% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. AlphaCentric Advisors LLC raised its position in Rapport Therapeutics by 6.8% in the 1st quarter. AlphaCentric Advisors LLC now owns 6,438 shares of the company’s stock worth $201,000 after purchasing an additional 408 shares during the last quarter. KBC Group NV bought a new position in Rapport Therapeutics in the 1st quarter worth approximately $30,000. State of Wyoming bought a new position in Rapport Therapeutics in the 2nd quarter worth approximately $65,000. Swiss National Bank raised its position in Rapport Therapeutics by 3.5% in the 1st quarter. Swiss National Bank now owns 56,500 shares of the company’s stock worth $1,768,000 after purchasing an additional 1,900 shares during the last quarter. Finally, Meeder Asset Management Inc. bought a new position in Rapport Therapeutics in the 2nd quarter worth approximately $116,000.

Rapport Therapeutics News Roundup

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: RAP-219 met both the primary and secondary endpoints, producing statistically significant placebo-adjusted improvements at Week 3 in the Young Mania Rating Scale total score and the Clinical Global Impression–Bipolar Severity of Mania score. The results support advancing RAP-219 toward later-stage development. Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219
• Positive Sentiment: The trial outcome has strengthened the commercial case for RAP-219. Jefferies estimated a potential peak-sales opportunity of roughly $1 billion, while coverage described the drug’s mechanism as potentially the first major new approach in bipolar mania treatment in decades. Inside the $1 Billion Blockbuster Opportunity
• Positive Sentiment: Analysts remained bullish following the data. HC Wainwright reaffirmed its Buy rating with a $66 price target, and BTIG raised its target from $75 to $89 while maintaining Buy. Wells Fargo also maintained its Buy rating.
• Neutral Sentiment: The positive announcement follows a sharp monthly decline and unusually heavy volume, suggesting the move may also reflect short-term repositioning and renewed speculative interest rather than a fully reassessed valuation. Why Is Rapport Therapeutics Stock Trading Higher Today?
• Negative Sentiment: Some analysts characterized the Phase 2 win as modest: RAP-219 met the prespecified goals but reportedly fell short of the trial’s original ambitions. Investors will still need to see durability, safety, and confirmatory Phase 3 results before assigning full blockbuster value. Rapport’s Phase 2 Bipolar Data

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines for neurological and psychiatric disorders. The company uses its proprietary RAP platform to identify and target synaptic receptor-associated proteins, which can influence the activity, distribution and function of receptors involved in the central nervous system.

Rapport’s lead clinical program is relutrigine, also known as RAP-219, an orally administered small-molecule therapy being developed for focal epilepsy.